Long-Acting Injectable Antipsychotic Medications in Schizophrenia Management
|
|
- Emery Miles
- 5 years ago
- Views:
Transcription
1 Sanika and Aparasu: Long-Acting Injectable Antipsychotic Medications in Schizophrenia Management 3507 International Journal of Pharmaceutical Sciences and Nanotechnology Volume 9 Issue 6 November December 2016 Review Article MS ID: IJPSN APARASU Long-Acting Injectable Antipsychotic Medications in Schizophrenia Management Sanika Rege and Rajender R. Aparasu Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, 1441 Moursund Street, Houston, Texas 77030, USA. Received October 25, 2016; accepted November 16, 2016 ABSTRACT Antipsychotic medications are indicated for the treatment of schizophrenia and other psychiatric disorders including bipolar disorder. However, oral antipsychotics are associated with a number of issues including poor treatment adherence. Long Acting Injectable (LAI) antipsychotics were designed to address these issues with oral antipsychotics. LAI antipsychotics offer several advantages including less frequent dose administration, better adherence and tolerability, and relapse prevention, which in turn help in improving patients quality of life. Recent development of atypical antipsychotics has the advantages over typical antipsychotics in terms of improved efficacy and tolerability. This review highlights the advantages and disadvantages of LAI antipsychotics, outlines the currently available LAIs and their indications, and real-world evidence for LAIs based on the observational studies. KEYWORDS: Antipsychotics; Injectables; efficacy; tolerability; quality of life. Introduction Long-acting injectable antipsychotics (LAIs) such as risperidone, paliperidone, aripiprazole, and risperidone are commonly used in the treatment of psychotic disorders, particularly schizophrenia (Jarema et al., 2015). The goals of schizophrenia treatment include improved function and recovery across lifespan, with symptom reduction and relapse prevention. LAIs were developed in order to overcome the drawbacks associated with oral antipsychotics such as poor medication adherence (Sacchetti et al., 2015). However, they are not solely used to improve patient s compliance, but also have other advantages including better tolerability, reduced frequency of administration, and maintenance of stable level of antipsychotics which assures better bioavailability. LAIs provide a persistent and effective blockade of dopaminergic D2 receptors in a range that is required to control psychotic symptoms, and also reduce the risk of abrupt treatment discontinuation (Jarema et al., 2015). Despite their widespread use, there are some concerns of LAIs due to slow dose titration, less flexibility of dose adjustment, longer time to achieve steady state levels, pain at injection site, and burden of frequent travel to outpatient clinics (Brissos et al., 2014). Historical Background of LAI Development The initial LAIs were based on first-generation antipsychotics or typical antipsychotics. Fluphenazine enanthate was developed as injectable in 1966 followed by development of fluphenazine decanoate, to address the issue of poor adherence to oral antipsychotics. Haloperidol decanoate became available in USA in 1986 (Brissos et al., 2014). The LAIs of second generation or atypical antipsychotics were recently developed to avail the advantages of both, improved efficacy and tolerability of atypical antipsychotics and increased compliance and better bioavailability of LAIs (Nahata and Saini, 2009; Offord et al., 2013; Brissos et al., 2014; Pesa 2015). Available LAI Products Currently, there are six LAI antipsychotics available for treatment of schizophrenia and other psychotic disorders. These include first-generation antipsychotics (Fluphenazine decanoate, and Haloperidol decanoate) and second-generation antipsychotics (Aripiprazole, Risperidone, Paliperidone and Olanzapine) (Jarema Brissos et al., 2014). Table 1 outlines the characteristics of various LAIs. Indications for LAI use Current guidelines recommend the use of LAI antipsychotics for the maintenance treatment of schizophrenia among other available treatment options and when there is a need to improve patient s medication adherence (Jaskelainen et al., 2013; Leucht et al., 2012; CG, 2005). Several guidelines recommend that LAI antipsychotics should be used only in patients with recurrent relapses related to partial or full nonadherence (Lehman et al., 2004; Lindenmayer, 2010; Mauri et al., 2014; LAIA, 2015; Marcus McEvan et al., 2016). 3507
2 3508 Int J Pharm Sci Nanotech Vol 9; Issue 6 November December 2016 Fluphenazine Fluphenazine mainly acts as a dopamine antagonist. Fluphenazine LAI is indicated in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenia). It is not intended for use in children under 12 years of age. Fluphenazine may be administered as a maintenance therapy in patients who have been stabilized on a fixed daily dosage of oral fluphenazine. Fluphenazine LAI is administered at a dose of mg at 1-4 weeks interval (AAP, 2010). Haloperidol Haloperidol blocks the dopamine receptors; however, its exact mechanism of action is not known. Haloperidol LAI is indicated for treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy. Haloperidol is not indicated in patients with severe toxic central nervous system depression, comatose patients, and in individuals hypersensitive to this drug or having Parkinson s disease. Haloperidol LAI should be administered in patients who have been previously stabilized with an oral antipsychotic, preferably oral haloperidol. The maintenance dose of haloperidol LAI must be individualized with titration and the usual maintenance dose range is 10 to 15 times the previous daily oral dose. It is administered in the dose range of mg every four weeks (LAIA, 2015). Risperidone Risperidone blocks the serotonin 5-HT 2A and 5-HT 7 receptors as well as dopamine D2 receptors. Risperidone LAI is indicated for the treatment of schizophrenia in patients presently treated with oral antipsychotics. It should be used with caution in patients with dementia and cerebrovascular disorders and is not indicated for patients below 18 years of age. Risperidone LAI should be administered to patients who have been treated with an antipsychotic, preferably oral risperidone. The period of oral risperidone treatment should be no shorter than 2 weeks. The maximum dosage of risperidone LAI is 50 mg every two weeks (JP, 2016; Mauri et al., 2014). Aripiprazole Aripiprazole is an antipsychotic agent that is sometimes referred to as the third-generation antipsychotic drug due to its unique mechanism of action; it is serotonergic 5-HT 2 antagonist as well as 5-HT 1A and D 2 partial agonist. Aripiprazole LAI is indicated for maintenance treatment of patients with schizophrenia who have been initially prescribed oral antipsychotics. It is not indicated in elderly patients with dementia and in patients under 18 years of age. It is associated with an increased risk of death, mainly due to cardiovascular causes. In patients who have been treated with oral aripiprazole, 400 mg of Aripiprazole LAI should be administered with simultaneous continuation of oral aripiprazole for 14 days in order to maintain stable serum aripiprazole levels. After 14 days, oral aripiprazole should be discontinued, and aripiprazole LAI should be given every four weeks (Jarema 2015; AW, 2014). Paliperidone Paliperidone blocks the monoamine activity with a strong affinity to serotonergic 5-HT 2A and dopaminergic D2 receptors. In addition, it also blocks the α-1, H1 and α-2 receptors, but does not bind to cholinergic receptors. Its central antagonistic action may be the reason for the lower incidence of extrapyramidal side-effects. Paliperidone LAI is indicated in adult schizophrenia patients after atleast one relapse or exacerbation of symptoms due to non-adherence to treatment; and should be used in patients who have been stabilized using risperidone or paliperidone treatment. If the patient is treated with another antipsychotic, they should first be switched to oral risperidone or paliperidone followed by paliperidone LAI. Paliperidone LAI is administered at a dose of mg at every four weeks interval (Mauri et al., 2014; JP, 2016 (a)). TABLE 1 Characteristics of LAI antipsychotics Name Fluphenazine decanoate Haloperidol decanoate Risperidone long-acting Year of approval Formulation Dose range (mg) Administration interval (weeks) Injection Site 1967 Sesame oil solution Gluteal 1986 Sesame oil solution Gluteal 2001 Aqueous suspension, risperidone encapsulated into biodegradable microspheres Gluteal or deltoid Half-life (days) (multiple dose) Time to reach peak plasma concentration (days) Monitoring post injection Reference No (Sacchetti Curry et al., 1979) No (Sacchetti Reyntijens et al., 1982; Kissling et al., 1991) No (Sacchetti Agid et al., 2010; Gefvert et al., 2005; Thyssen et al., 2010) TABLE 1 Contd
3 Sanika and Aparasu: Long-Acting Injectable Antipsychotic Medications in Schizophrenia Management 3509 Name Paliperidone palmitate Olanzapine pamoate Aripiprazole long-acting Year of approval Formulation 2009 Aqueous suspension of nanoparticles 2009 Aqueous microcrystalline suspension Aqueous suspension microparticles Dose range (mg) Administration interval (weeks) Injection Site Gluteal or deltoid Gluteal Gluteal Half-life (days) (multiple dose) Time to reach peak plasma concentration (days) Monitoring post injection Reference No (Sacchetti Gilday and Nasrallah, 2012) Yes (3 hours) (Sacchetti Agid et al., 2010; Rosaria and Alice, 2010) No (Sacchetti Nahata and Saini, 2009) Olanzapine Olanzapine is an antipsychotic that has affinity towards multiple receptors including serotonergic 5-HT 2A and 5-HT 2C, 5-HT 3, 5-HT 6, dopaminergic D1-D5, muscarinic M1-M5, adrenergic α-1 and histaminergic H1 receptors. This multi-receptor affinity is probably associated with its antipsychotic effectiveness. Olanzapine LAI is indicated for maintenance treatment of adult schizophrenia patients who have been stabilized by oral olanzapine. They are not recommended for patients aged 65 years or older, or for children and adolescents. They are also not indicated for patients with renal and liver failure. Olanzapine LAI should be administered in patients already stabilized on oral olanzapine, usually mg at four weeks interval (Jarema Lindenmayer, 2010). Real World Evidence of LAIs LAIs and Hospital Re-admission Rates In a retrospective cohort study conducted by McEvan et al., lower probability (adjusted OR = 0.60, 95% CI = ) of re-hospitalization was observed for LAIs compared to oral antipsychotics for schizophrenia patients (McEvan et al., 2016). Similar results were observed in a study by Marcus et al. in adult schizophrenia patients with a recent history of nonadherence. Patients who were initiated LAIs, had lower odds (adjusted OR = 0.73, 95% CI = ) of rehospitalization compared to those receiving oral antipsychotics (Marcus et al., 2015). Another study evaluated the risk of re-hospitalization among patients with schizophrenia and LAIs. In this study, the adjusted odds ratio for re-hospitalization risk was 0.80 (95% CI = ), compared to the oral antipsychotics group (Ju 2014). Also, in a study evaluating the association between second generation antipsychotic medication half-life and hospitalization in adult schizophrenia, a significantly lower rate of hospitalization was evident for long half-life (0.74/patient-year) compared to short half-life (1.06/patient-year) antipsychotics (Broder et al., 2012). LAIs Cost and Resource Utilization Schizophrenia represents 1.5-3% of national healthcare expenditures, hence cost-effective treatment is essential to ensure reduction in disease burden and efficient resource utilization (Brissos et al., 2014). Many retrospective studies have been conducted to determine the cost and resource utilization in patients using LAI antipsychotics. A study by Pesa et al., found that schizophrenia patients who were prescribed paliperidone palmitate had higher per-month mental-health prescription costs, however they had lower inpatient and outpatient care costs. Use of paliperidone palmitate resulted in 0.44 times reduction in all-cause hospitalizations and 0.47 times reduction in the odds of mental-health-related hospitalizations, compared to oral atypical antipsychotics, over a twelve-month follow-up period (Pesa et al., 2015). Similar results were observed in a study conducted by Baser et al., where schizophrenia patients from Veterans Health Administration treated with paliperidone palmitate had lower inpatient costs ($18,560 vs. $31,505, p=0.002) and lower frequency of hospitalization (34% vs. 53%, p<0.001) compared to patients with oral atypical antipsychotics (Baser et al., 2015). Lin et al. observed that among schizophrenia patients, LAI users had lower schizophrenia-related hospital costs during the follow-up period compared to the pre-index period, but oral antipsychotic users had increased costs ($5,981 ± $16,554 vs. $758 ± $14,328, p<0.001) (Lin et al., 2013). Offord et al. observed that schizophrenia patients initiating LAI vs oral antipsychotics, showed significantly greater reduction in the average number of all-cause hospitalizations (-0.90 ± 1.77 vs ± 1.49, p < 0.001), length of stay (-10.3 ± 23.2 vs. 0.7 ± 16.7 days, p < 0.001) and schizophreniarelated hospitalizations (-0.60 ± 1.37 vs ± 0.99, p < 0.001) (Offord et al., 2013). Comparative Effectiveness of LAIs In a Medicaid claims database study, patients who switched from risperidone LAI to paliperidone palmitate had fewer events (schizophrenia-related hospitalization) (26 vs. 32), longer time to event (mean 70 vs. 47 days), and lower risk of relapse (HR= 0.54, 95% CI= )
4 3510 Int J Pharm Sci Nanotech Vol 9; Issue 6 November December 2016 compared to those who switched from risperidone LAI to oral antipsychotics (Voss et al., 2015). In another study comparing risperidone and paliperidone LAIs, significantly lower discontinuation rates (36.5% vs. 53.3%, p<0.001) and longer days of LAI coverage (233.6 vs days, p<0.001) were associated with paliperidone. Also, patients treated with paliperidone palmitate were 12.5 times (95% CI= ) more likely to be adherent based on medication possession ratio and 11.7 times (95% CI= ) more likely to be adherent based on proportion of days covered (Joshi et al., 2016). Conclusions Based on the findings of observational studies, compared to oral antipsychotics, LAIs were found to be associated with significantly lower re-hospitalizations, better medication adherence, and lower all-cause and schizophrenia-related costs of hospitalizations; thus ensuring effective resource utilization, reduced disease burden and pharmaceutical costs of schizophrenia (Reyntijens et al., 1982; Rosaria and Alice, 2010; Sacchetti Thyssen et al., 2010). LAI antipsychotics provide a valuable treatment option for individualized and personalized treatment of schizophrenia. LAIs have shown to be associated with reduced hospital readmissions, improved treatment adherence, and reducing the costs and burden of the disease. Although there has been recent emergence of LAI atypical antipsychotics, there is a need to evaluate comparative effectiveness and safety for patients with schizophrenia due to cost and quality of care concerns. Also, well-designed long-term studies are needed to evaluate its role in other psychiatric disorders. References Agid O, Foussias G, and Remington G (2010). Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 11: APP Pharmaceuticals (2010). Fluphenazine decanoate Injection USP. Available at drugsatfda_ docs/label/2010/071413s019lbl.pdf. Accessed 3 rd November Avon and Wiltshire (2014). Mental Health Partnership NHS Trust, Aripiprazole long acting injection (Abilify Maintena), Guidance for prescribing and administration, Prescribing Guidelines V1.1 BLS. Baser O, Xie L, Pesa J, and Durkin M (2015). Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ 18: Brissos S, Veguilla MR, Taylor D, and Martinez VB (2014). The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 4: Broder MS et al (2012). Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia. J Med Econ 15: CG (2005). Canadian guidelines. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 50: 7S-57S. Curry S, Whelpton R, de Schepper P, Vranckx S, and Schiff A (1979). Kinetics of fluphenazine after fluphenazine dihydrochloride, ethanthate and decanoate administration to man. Br J Clin Pharmacol 7: Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, and Mannaert E (2005). Pharmacokinetucs and D2 receptor occupancy of long-acting injectable risperisone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 8: Gilday E and Nasrallah H (2012). Clinical pharmacology of paiperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials 7: 2-9. Jaaskelainen E, Juola P, and Hirvonen N (2013). A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 39: JP (2016a). Janssen Pharmaceuticals, Inc Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use, Highlights of prescribing information Available at product/invegasustenna/prescribing-information.pdf. Accessed 4 th November JP (2016b). Janssen Pharmaceuticals, Inc., Risperdral Consta (risperidone) long-acting injection, Highlights of prescribing information Available atttp:// product/risperdalconsta/prescribing-information.pdf. Accessed 4 th November Jarema M (2015). Practical Guidelines for the use of long-acting injectable second-generation antipsychotics. Psychiatr Pol 49: Joshi K, Pan X, Wang R, Yang E, and Benson C (2016). Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Curr Med Res Opin 32: Ju PC (2014). Long-acting injectables for rehospitalization among patients with schizophrenia in the home care program in Taiwan. J Clin Psychopharmacol 34: Kissling W, Moller H, Walter K, Wittmann B, Krueger R, and Trenk D (1991). Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmacopsychiatry 18: Lehman A, Lieberman J, Dixon L, McGlashan T, Miller A, and Perkins D (2004). American Psychiatric Association; Steering Committee on Practice Guidelines, Practice Guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 (2 Suppl.): Leucht S, Tardy M, and Komossa K (2012). Antipsychotic drugsversus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379: Lin J, Wong B, Offord S, and Mirski D (2013). Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res 40: Lindenmayer JP (2010). Long-acting injectable antipsychotics: focus on olanzapine pamoate.neuropsychiatr Dis Treat 6: LAIA (2015). Long-acting Injectable Antipsychotics: Haloperidol and fluphenazine decanoate, aripiprazole (Abilify Maintena), risperidone (Risperdal Consta), and paliperidone (Invega Sustenna), Criteria for use and evidence summary, VA Pharmacy Benefits Management Services 2015, Available at accessed 29 th October Marcus (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Mang Care Spec Pharm 21: Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, and Altamura AC (2014). Clinical pharmacology of atypical antipsychotics: an update. Excli J 13: McEvan JP (2016). Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv 67: Nahata T and Saini T (2009). Formulation optimization of longacting depot injection of aripiprazole by using D-optimal mixture design. PDA J Pharm Sci Technol 63:
5 Sanika and Aparasu: Long-Acting Injectable Antipsychotic Medications in Schizophrenia Management 3511 Offord S, Wong B, Mirski D, Baker RA, and LinJ (2013). Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 16: Pesa JA (2015). Costs and Resource Utilization among Medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs Real World Outcomes 2: Reyntijens A, Heykants J, Woestenborghs R, Gelders Y and Aerts T (1982). Pharmacokinetics of haloperidol decanoate. Int Pharmacopsychiatry 17: Rosaria D and Alice B (2010). Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat 6: Sacchetti E (2015). Long-acting injection antipsychotic medications in the management of schizophrenia. Evidence-based Psychiatric Care 1: Thyssen A, Rusch S, Herben V, Quiroz J and Mannaert E (2010). Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal in schizophrenic patients. J Clin Pharmacol 50: Voss EA, Ryan PB, Stang PE, Hough D and Alphs L (2015). Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of Medicaid claims database. Int Clin Psychopharmacol 30: Address correspondence to: Dr. Rajender R. Aparasu, Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston Texas Medical Center Suite 425, 1441 Moursund Street Houston, Texas 77030, USA. rraparasu@uh.edu
Abbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAntipsychotic agents are the mainstay of treatment for patients
Long-acting injectable antipsychotics: What to do about missed doses Use a stepwise approach based on the unique properties of the specific medication Jasmine Carpenter, PharmD, BCPS, BCPP PACT/Mental
More informationLiterature Scan: Parenteral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLAI Antipsychotics Frequently Asked Questions
LAI Antipsychotics Frequently Asked Questions Click each question to see the answer. Click the link to return to this list. Who should receive LAIs (long acting injectable antipsychotics)? Which antipsychotics
More informationClinician's Guide to Prescribing Depot Antipsychotics
Handout for the Neuroscience Education Institute (NEI) online activity: Clinician's Guide to Prescribing Depot Antipsychotics Learning Objectives Explain the benefits and risks of depot antipsychotics
More informationAPPLYING ANTIPSYCHOTIC PHARMACOKINETICS TO BEST DOSING PRACTICES: DEPOT MEDICATIONS
APPLYING ANTIPSYCHOTIC PHARMACOKINETICS TO BEST DOSING PRACTICES: DEPOT MEDICATIONS Objectives Review the kinetic parameters of depot antipsychotics Review loading strategies for those depot medications
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationNew Medicines Committee Briefing November 2011
New Medicines Committee Briefing November 2011 Paliperidone long-acting injection (Xeplion ) for schizophrenia Paliperidone palmitate long-acting injection (Xeplion ) is to be reviewed for use within:
More informationEffectiveness of paliperidone long-acting injection in clinical practice.
Ther Adv Psychopharmacol (2018) 1 7 doi: 10.1177/ 2045125317753332 Effectiveness of paliperidone long-acting injection in clinical practice. Paul Nicholas Deslandes 1,2, Elan Haf Ward 3, Kathryn Norris
More informationEffects of Discontinuation of Paliperidone Long-Acting Injectable After Switching from Risperidone Long-Acting Injectable Switching
Evidence-Based Medicine Key Words: antipsychotics, paliperidone palmitate, risperidone, long-acting injectable, successful switching, discontinuation Effects of Discontinuation of Paliperidone Long-Acting
More informationKey Words: schizophrenia, psychopharmacology, antipsychotic medication, long-acting injectable antipsychotics; paliperidone palmitate
Evidence-Based Medicine Key Words: schizophrenia, psychopharmacology, antipsychotic medication, long-acting injectable antipsychotics; paliperidone palmitate Long-Acting Injectable Paliperidone Palmitate:
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationGUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)
GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) Introduction Aripiprazole long-acting injection (LAI)is licensed for the maintenance treatment of adult patients with schizophrenia
More informationImproving Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment
Improving Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment page 247 in syllabus Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San
More informationpaliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd
Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium
More informationIn February 2013, the FDA approved a
Long-acting injectable aripiprazole for adult schizophrenia Jana Lincoln, MD Depot formulation and once-monthly dosing might improve adherence in patients with schizophrenia 46 May 2013 In February 2013,
More informationMaking the Business Case for Long-Acting Injectables
Making the Business Case for Long-Acting Injectables David R. Swann, MA, LCAS, CCS, LPC, NCC Senior Healthcare Integration Consultant MTM Services Chief Clinical Officer Partners Behavioral Health Management
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationFebruary 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by
February 7-9, 2019 The Westin Fort Lauderdale Florida Provided by Addressing Your Greatest Concerns in Schizophrenia Management: From Suicide to Relapse Prevention and the Role of LAIs John Lauriello,
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationAre Two Antipsychotics Better Than One?
Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office
More informationINJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM
SUBMIT TO Utilization Management Department Phone: 1.866.912.6285 Fax: 1.866.694.3649 MEMBER INFORMATION INJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM Fax completed form to Cepatico at 866.694.3649. Upon
More informationLocal Policy Recommendation
Local Policy Recommendation Aripiprazole (Abilify Maintena ) prolonged-release (PR) suspension for injection/long-acting antipsychotic injection (LAI) Recommendation: Red Aripiprazole prolonged-release
More informationRegier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016;
Regier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016; Miyamoto 2017 Risperdal Consta (risperidone) Zyprexa Relprevv (olanzapine pamoate) Invega Sustenna (paliperidone palmiate)
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationNebraska Medicaid Criteria. Abilify Maintena
Nebraska Medicaid Criteria All initial and renewal authorizations are for 12 months in duration. Abilify Maintena *Criteria for Authorization for Abilify Maintena The individual has a current DSM diagnosis
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationModel-based Approaches to Assist Clinical Development of Psychiatric Products
Model-based Approaches to Assist Clinical Development of Psychiatric Products Session Chair: Hao Zhu, Ph.D., Co-chair: Mitchell Mathis, M.D., ASCP Meeting (May, 2017) Agenda 1. Presentation Exposure-Response
More informationThe Use of Long Acting Injectable Antipsychotics: More Practical Considerations
The Use of Long Acting Injectable Antipsychotics: More Practical Considerations The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationCurrent Medical Research and Opinion. ISSN: (Print) (Online) Journal homepage:
Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: https://www.tandfonline.com/loi/icmo20 Short-term rehospitalizations in young adults with schizophrenia
More informationOral antipsychotic nonadherence is a
Risperidone extended-release injectable suspension Jonathan M. Meyer, MD Oral antipsychotic nonadherence is a significant contributor to relapse in patients with schizophrenia spectrum disorders. Long-acting
More informationLong Acting Injectable (LAI) Atypical Antipsychotic Drugs: A Practical Guide for Nursing. Lucinda Whitney DNP, APRN, PMHNP-BC
Long Acting Injectable (LAI) Atypical Antipsychotic Drugs: A Practical Guide for Nursing Lucinda Whitney DNP, APRN, PMHNP-BC Disclosures I have no pertinent financial disclosures Information provided here
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationJanssen-Cilag 50 years of innovation. This supplement was supported by Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N.V.
Janssen-Cilag 50 years of innovation This supplement was supported by Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N.V. Janssen-Cilag 50 years of innovation For more than 50 years, Janssen-Cilag
More informationDepots Improving patient care?
Depots Improving patient care? Caroline Parker Consultant Pharmacist NAPICU Conference 9 th September 2010 Depots Coercion Paternalistic Degrading Standard treatment Necessary Old fashioned Forced Easier
More informationDosing and Switching Strategies for Long-Acting Risperidone
Clinical Guidelines: Dosing Long-Acting Risperidone Clinical Guidelines Dosing and Switching Strategies for Long-Acting Risperidone Stephen R. Marder, M.D.; Robert Conley, M.D.; Larry Ereshefsky, Pharm.D.,
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSTEP THERAPY CRITERIA
DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)
More informationAntipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationMr. E, age 37, has a 20-year history
Antipsychotics for obsessive-compulsive disorder: Weighing risks vs benefits Taylor Modesitt, PharmD, Traci Turner, PharmD, BCPP, Lindsay Honaker, DO, Todd Jamrose, DO, Elizabeth Cunningham, DO, and Christopher
More informationWhat Team Members Other Than Prescribers Need To Know About Antipsychotics
What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
More informationComparison of Atypical Antipsychotics
PL Detail-Document #281006 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2012 Comparison of
More informationPALIPERIDONE (Trevicta ) 3 MONTHLY Long acting injection (LAI) Guidance for Prescribing and Administration
PALIPERIDONE (Trevicta ) 3 MONTHLY Long acting injection (LAI) Guidance for Prescribing and Administration Paliperidone 1 monthly long acting injection (Xeplion ) This is included in the Trust medicines
More informationDEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING
DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING DECEMBER 2016 This policy supersedes all previous policies Policy title Depot Antipsychotic Medication: Guidelines for Prescribing
More informationANTIPSYCHOTIC POLYPHARMACY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University
More informationLurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action
Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationRole of depot antipsychotic medication in long-term antipsychotic treatment
Role of depot antipsychotic medication in long-term antipsychotic treatment SCOPING QUESTION: In individuals with psychotic disorders (including schizophrenia) who require long-term antipsychotic treatment,
More informationMental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service
Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact
More informationA review of the efficacy and tolerability of antipsychotic long-acting injections
A review of the efficacy and tolerability of antipsychotic long-acting injections Allison Whyte MPharm-IP, Caroline Parker FFRPS, FRPharmS, FCMHP The formulation of long-acting injections (LAIs) as a method
More informationAWMSG SECRETARIAT ASSESSMENT REPORT (FULL SUBMISSION)
AWMSG SECRETARIAT ASSESSMENT REPORT (FULL SUBMISSION) Advice No. 2512 Paliperidone palmitate (Xeplion ) 50 mg, 75 mg, 100 mg and 150 mg prolonged release suspension for injection In collaboration with
More informationComparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics
Research Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Dante M Durand,1, Phillip Harvey 1,2, Ricardo Cáceda 3 ABSTRACT Introduction: Clozapine
More informationCosts and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
Drugs - Real World Outcomes (2015) 2:377 385 DOI 10.1007/s40801-015-0043-4 ORIGINAL RESEARCH ARTICLE Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone
More informationCynthia A Bossie 1*, Jennifer K Sliwa 1, Yi-Wen Ma 2, Dong-Jing Fu 1 and Larry Alphs 1. Abstract
RESEARCH ARTICLE Open Access Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial Cynthia
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationMental Health Subcommittee of PTAC meeting held 21 June (minutes for web publishing)
Mental Health Subcommittee of PTAC meeting held 21 June 2010 (minutes for web publishing) Mental Health Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationAddressing an Underutilized Best Practice for Severe and Persistent Mental Illness: Long-Acting Injectables
Addressing an Underutilized Best Practice for Severe and Persistent Mental Illness: Long-Acting Injectables TREATMENT CHALLENGES People with severe and persistent mental illness (SPMI) are at significant
More informationRexulti (brexpiprazole)
Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017
Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017
Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationUse of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
More informationLurasidone In Vitro Receptor Binding
Lurasidone Lurasidone In Vitro Receptor Binding 5-HT 2A D 2 Log of Ki Values (nm) M 1 * 5-HT 7 5-HT 1A α 2C α H 1 * 2A 0.1 1 10 100 1000 10000 HIGH AFFINITY Dopamine D 2 Serotonin 5-HT 2A Serotonin 5-HT
More informationLAO Aripiprazole OW Long Acting Oral aripiprazole Once Weekly
LAO Aripiprazole OW Long Acting Oral aripiprazole Once Weekly An alternative option to Long Acting Injectables (LAI) in the rapidly expanding market for prevention of psychotic relapse Zysis Management
More informationFDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extendedrelease injectable suspension in the Treatment of Schizophrenia
FOR IMMEDIATE RELEASE FDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extendedrelease injectable suspension in the Treatment of Schizophrenia Patients being treated for schizophrenia
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationPlatforms for Performance: Clinical Dashboards to Improve Quality and Safety 2011 Midyear Clinical Meeting
Improving Mental Health Outcomes in Veterans Through Dashboard Technology Learning Objectives 1. Describe VA Academic Detailing 2. Show how an increase in metabolic monitoring and a decrease in off-label
More informationAdvancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study. Finding Clarity in the Midst of Uncertainty
Advancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study Finding Clarity in the Midst of Uncertainty Agenda Medication adherence in serious mental illness Consequences
More informationNational Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS
National Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS Key Points for RWE in Randomized Clinical Trials What is the
More informationLAIs and the Challenge of Medication Non-Adherence The Care Transitions Network
LAIs and the Challenge of Medication Non-Adherence The Care Transitions Network Lauren Hanna, M.D. The Zucker Hillside Hospital Northwell Health National Council for Behavioral Health Montefiore Medical
More informationARIPIPRAZOLE. THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names. Generic? Yes
ARIPIPRAZOLE THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine, serotonin receptor partial agonist
More informationSchizophrenia, a devastating chronic. Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program
Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program Joseph Menzin, Ph.D. Luke Boulanger, M.A. Mark Friedman, M.D. Joan Mackell, Ph.D. John R.
More informationTable 2. Distribution of Normalized Inverse Probability of Treatment Weights. Healthcare costs (US $2012) Notes:
228 COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND MEDICAID SPENDING AMONG PATIENTS WITH SCHIZOPHRENIA TREATED WITH ONCE MONTHLY PALIPERIDONE PALMITATE OR ORAL ATYPICAL ANTIPSYCHOTICS USING THE INVERSE
More informationGuidance on the Use of Antipsychotic Long-acting Injections in North of England
Guidance on the Use of Antipsychotic Long-acting Injections in North of England This guidance aims to inform and support prescribers within the three mental health service providers in the north of England
More informationIs there a case for earlier use of antipsychotic LAIs in schizophrenia? John Donoghue Liverpool
Copyright John Donoghue 2017 Is there a case for earlier use of antipsychotic LAIs in schizophrenia? John Donoghue Liverpool If not us, then who? If not now, when? Attributed at different times to: Hillel
More informationAntipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationRUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1
RUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1 Efficacy of Long Acting Injectable Antipsychotics in Early Onset Schizophrenia Linda Pietras RN-BC Mercyhurst University
More informationInvega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent
Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent Noor Daghistani, PharmD; and Jose A. Rey, PharmD, BCPP INTRODUCTION Schizophrenia is a chronic mental illness known
More informationProposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)
Proposed Changes to Existing Measure for HEDIS 1 2020: Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) NCQA seeks comments on proposed modifications to the HEDIS Health
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationTable of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
More informationMinimising the Impact of Medication on Physical Health in Schizophrenia
Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,
More informationDo Large Scale Studies of the Use of Antipsychotics Help Us Choose the Most Effective Treatments for Schizophrenia?
Do Large Scale Studies of the Use of Antipsychotics Help Us Choose the Most Effective Treatments for Schizophrenia? Mark Agius 1,2. Jesus Perez 2,3. 1. SEPT: South Essex Partnership University NHS Foundation
More informationResearch and Reviews: Journal of Pharmacy and Pharmaceutical Sciences
Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences A Validated Spectrophotometric Method for Determination of Paliperidone Palmitate in Bulk Drug and its Pharmaceutical Dosage Form.
More informationTreat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering
Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective
More informationAnirban Basu The Comparative Outcomes, Policy, and Economics (CHOICE) Institute University of Washington, Seattle
Projections to Real-World Population Potential Impact of Using Paliperidone Palmitate Long-Acting Injections Among Medicaid Beneficiaries With Schizophrenia Anirban Basu The Comparative Outcomes, Policy,
More informationPALIPERIDONE. THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names
PALIPERIDONE THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn)
More informationPreventing relapse in schizophrenia: a real priority or only a tick-box exercise? John Donoghue Liverpool
Preventing relapse in schizophrenia: a real priority or only a tick-box exercise? John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Copyright John Donoghue 2013 These
More information